Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 19Ovarian Neoplasms 17Neuroblastoma 15Fallopian Tube Neoplasms 13Neoplasms 6Carcinoma, Ovarian Epithelial 6Ganglioneuroblastoma 5Brain Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Neoplasm Metastasis 3Lung Neoplasms 3Glioma 3Central Nervous System Neoplasms 3Sarcoma, Ewing 2Rhabdoid Tumor 2Retinoblastoma 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Wilms Tumor 1Thrombocythemia, Essential 1SCLC, Extensive Stage 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Topotecan × 1 year × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡